Understanding Drug Sensitivity and Tackling Resistance in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immune-suppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Similarly, the analysis of metastatic melanoma samples by single-cell RNA sequencing identified heterogeneous cell states across tumor cells as well as tumor-infiltrating immune cells (106).”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 2×
“The list of potential causes for drug resistance is lengthy and has included clonal evolution of tumors toward a resistant clone (1), increased expression and/or activity of multidrug efflux pumps (2), the elusive nature of cancer stem cells (3) and the role of shifting epigenetic states in shaping plasticity of these…”
BackgroundIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201 · cited 1×
“Furthermore, cross-cancer evaluations spanning different cancer entities identified reoccurring pathway alterations across RTK-RAS-MAPK, PI3K, cell cycle, TP53, Notch, MYC, Hippo, WNT, TGFB1, and NRF2 signaling pathways (93).”
BackgroundSelf-citationGreaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162 · cited 2×
“The list of potential causes for drug resistance is lengthy and has included clonal evolution of tumors toward a resistant clone (1), increased expression and/or activity of multidrug efflux pumps (2), the elusive nature of cancer stem cells (3) and the role of shifting epigenetic states in shaping plasticity of these…”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
“Continued advancements in understanding cancer biology and drug resistance will enhance the role of targeted therapies in improving patient outcomes and advancing cancer treatment [38].”
BackgroundPlant-Derived Nanovesicles: Further Exploration of Biomedical Function and Application Potential
Li, A., Li, D., Gu, Y., Liu, R., Tang, X., Zhao, Y., Qi, F., Wei, J., & Liu, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.022 · Cited by 137
Learning chemical sensitivity reveals mechanisms of cellular response
Connell, W., Garcia, K., Goodarzi, H., & Keiser, M. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06865-4 · Cited by 4
Metadata
- Authors
- Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., Druker, B. J., Hutson, A. D., Nelson, P. S., Sawyers, C. L., & Willey, C. D.
- Venue
- Cancer Research
- Published
- 2022-02-21
- Volume
- 82
- Issue
- 8
- Pages
- 1448-1460
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4213449305
- Cited by
- 78
- References
- 64
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding Drug Sensitivity and Tackling Resistance in Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-3695
- The paper
- Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., Druker, B. J., Hutson, A. D., Nelson, P. S., Sawyers, C. L., & Willey, C. D. (2022). Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-3695
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.